Milestone Pharmaceuticals Inc. (NASDAQ:MIST) moved closer to potential FDA approval for its Cardamyst (etripamil) nasal spray, an investigational therapy for paroxysmal supraventricular tachycardia (PSVT), as the U.S. Food and Drug Administration (FDA) accepted the company’s response to prior issues.
However, shares of Milestone Pharmaceuticals plummeted over 36% on Friday following the pricing of a public offering that includes common shares and accompanying warrants, signaling potential dilution for existing shareholders.
